Clinical Trial Update: Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions [Phase 4]

View source ↗

Summary

Pfizer completed a Phase 4 trial evaluating the safety and efficacy of 0.3 mg/eye pegaptanib (Macugen) in patients with small age-related macular degeneration l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Pfizer | Conditions: Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2009-10-02